Gosset Ownership
Private
Employees
~17
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Blaze Bioscience General Information
Completed enrollment for pivotal Phase 2/3 trial of tozuleristide and the Canvas Imaging System in pediatric central nervous system tumors. BLZ-100 (tozuleristide) received Fast Track Designation from FDA for pediatric central nervous system tumors. Clinical proof-of-concept has been demonstrated in brain, breast, and skin cancer.
Contact Information
Primary Industry
Biotech
Corporate Office
Seattle, Washington
United States
United States
Drug Pipeline
tozuleristide
Phase 2/3Key Partnerships
Fred Hutchinson Cancer Research Center, Pacific Pediatric Neuro-Oncology Consortium (PNOC), unidentified pharmaceutical company for immuno-oncology pipeline
Blaze Bioscience Funding
No funding data available
To view Blaze Bioscience's complete valuation and funding history, request access »